[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"corticobasal-syndrome-cbs\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:corticobasal-syndrome-cbs":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,93],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100636721","a-wearable-sensor-platform-for-remote-monitoring-of-individuals-on-the-frontotemporal-dementia-spectrum-100636721",false,"NCT07569367","A Wearable Sensor Platform for Remote Monitoring of Individuals on the Frontotemporal Dementia Spectrum","ReMoTe","Inclusion Criteria:\n\n* Male and female participants aged 40 years or older with a clinical diagnosis of possible or probable FTLD syndrome phenotype.\n* Participants must be fluent in reading and speaking English and must be capable of providing informed consent based on the principal investigator's judgment.\n* Individuals eligible for inclusion must be able to comply with the protocol per the investigator's judgment and must have a caregiver or study partner who is willing and able to assist with all study-related procedures.\n\nExclusion Criteria:\n\n* Any neurological, medical, or psychiatric condition that would preclude or confound participation in study activities based on the investigator's judgment.\n* Individuals who have a history of frequent falls defined as more than 5 falls per month.","ALL","40 Years",{"count":19,"type":20},60,"ESTIMATED","OBSERVATIONAL","The primary objective of this clinical study is to provide the initial validation for monitoring biomarkers of symptoms and functioning for individuals with frontotemporal lobar degeneration (FTLD) syndromes. Researchers at BioSensics, Johns Hopkins University School of Medicine, and Massachusetts General Hospital will use wearable sensors, computerized speech, psychomotor, and cognitive assessments to create outcome measures and digital biomarkers for FTLD syndromes. Researchers will deploy this digital health solution to monitor 60 patients with FTLD syndromes for 24 months with study visits every 6 months.",[24,25,26,27],"Frontotemporal Lobar Degeneration (FTLD)","Frontotemporal Dementia (FTD)","Corticobasal Degeneration","Corticobasal Syndrome (CBS)",[29,30,31],"digital health","wearable sensors","frontotemporal lobar degeneration","NOT_YET_RECRUITING","2026-05-05",{"date":35,"type":36},"2026-05-08","ACTUAL",{"date":38,"type":20},"2026-08-01",{"date":40,"type":20},"2030-12-15",{"name":42,"class":43},"BioSensics","INDUSTRY",2,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":55,"conditions":56,"keywords":75,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":92},"100565858","the-curepsp-genetics-program-100565858","NCT06647641","The CurePSP Genetics Program","Inclusion Criteria:\n\n1. Adults (aged 35 or older) with a clinical diagnosis of PSP, CBS, MSA, or a related neurological disease as confirmed by their healthcare provider, or unaffected family members of participants who have reported a family history of relevant neurodegenerative conditions.\n2. Meet Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Possible or Probable PSP (32), clinically established or clinically probable MSA (33), Armstrong criteria (2013) for possible or probable CBS (34). Diagnostic certainty will be determined by the treating\u002Freferring clinician.\n3. Willingness to undergo genetic testing. Participants will have the option to receive relevant genetic test results.\n4. Have the capacity to give full informed consent in writing or electronically, or provide consent through a legally authorized representative (LAR)\u002Fpower of attorney (POA), and have read, understood, and completed the informed consent form.\n5. Are able to perform or have a designee who can perform study activities (including completion of either online or orally administered surveys).\n\nExclusion Criteria:\n\n1. Individuals who have received a blood transfusion within the past 3 months.\n2. Individuals who have active hematologic malignancies such as lymphoma or leukemia.\n3. Individuals who have had a bone marrow transplant within the past 5 years.\n4. Individuals under the age of 35 or age of majority in applicable states at the time of consenting.",true,"35 Years",{"count":54,"type":20},1000,"This study is an observational, prospective genetic study. It aims to obtain DNA for research and testing from patients with PSP, CBS, MSA, and related neurological conditions and their families.\n\nUp to 1,000 adults who have been clinically diagnosed with PSP, CBS, MSA, or related neurological conditions will be enrolled. The study intervention involves sequencing of participant blood samples using non-CLIA-approved whole genome sequencing at the National Institutes of Health. Pathogenic variants that are deemed possibly related to these conditions will be confirmed using CLIA-approved testing. The study involves minimal risk to participants.",[57,58,59,60,61,26,62,27,63,64,65,66,67,68,69,70,71,72,73,74],"PSP","PSP - Progressive Supranuclear Palsy","Corticobasal Syndrome","Corticobasal Syndrome(CBS)","Corticobasal Degeneration Syndrome","Corticobasal Degeneration (CBD)","MSA","MSA - Multiple System Atrophy","MSA-C","Multiple System Atrophy","Multiple System Atrophy (MSA) With Orthostatic Hypotension","Multiple System Atrophy - Cerebellar Subtype (MSA-C)","Multiple System Atrophy - Parkinsonian Subtype (MSA-P)","Multiple System Atrophy, Cerebellar Type","Multiple System Atrophy, Parkinsonian Type","Progressive Supranuclear Palsy","Progressive Supranuclear Palsy(PSP)","Progressive Supranuclear Palsy (PSP)",[76,72,66,77,78,57,63,79,80],"genetic study","Corticobasal","CurePSP","CBD","Genes","RECRUITING","2026-01-12",{"date":84,"type":36},"2026-01-14",{"date":86,"type":36},"2024-10-08",{"date":88,"type":20},"2030-12-31",{"name":90,"class":91},"Massachusetts General Hospital","OTHER",1,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":51,"sex":16,"minAge":101,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":104,"conditions":105,"keywords":107,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":92},"100593008","imaging-studies-in-corticobasal-syndrome-100593008","NCT07000851","Imaging Studies in Corticobasal Syndrome","Neuroinflammation, White Matter Integrity, AD Biomarkers and Pathology in Corticobasal Syndrome","I-CAN","Inclusion Criteria:\n\n* Age 18 years or older\n* Meet possible or probable CBS criteria\n\nExclusion Criteria:\n\n* Subjects will be excluded if MRI is contraindicated (due to implanted device, severe claustrophobia, etc)\n* Subjects will be excluded if they have a concurrent illnesses or structural abnormality that could account for the CBS syndrome\n* Subjects will be excluded if they have a mutation in the progranulin gene\n* Subjects will excluded if they have received anti-Aβ therapy\n* Women who are pregnant will be excluded\n* Subjects will be excluded if they are actively taking daily anti-inflammatory medications (NSAIDs, corticosteriods, etc)\n* Subjects will be excluded if they have generalized inflammatory condition and treatment with immunosuppressive, corticoid\u002Fglucocorticoid, steroidal or non-steroidal anti-inflammatory medication within 2 weeks of scanning","18 Years",{"count":103,"type":20},80,"The primary goal of this study is to investigate inflammation and white matter damage in corticobasal syndrome and determine whether these processes are related to each other. The investigator's will address our goal by using neuroimaging and blood plasma biomarkers, as well as molecular pathology.",[106,59,60,26,62,27],"Cortico Basal Degeneration",[108,109,110,111,112,113],"neurodegeneration","neurodegenerative disease","cbs","cbd","corticobasal syndrome","corticobasal degeneration","2025-07-03",{"date":116,"type":36},"2025-07-07",{"date":118,"type":36},"2025-06-25",{"date":120,"type":20},"2031-03-30",{"name":122,"class":91},"Jennifer Whitwell"]